Current strategies target mutant RAS proteins either directly[108] or by identifying vulnerabilities in oncogene-addicted tumor cells.[109,110] A unique approach suggests inducing synthetic lethality in Kras-mutant tumors by targeting the oncogenic stress caused by Kras mutation. This evidence concerns the gene KRAS and neoplasm.